Rare Disease Genome Editing Global Market Report 2026

Rare disease genome editing involves the application of precise genetic modification techniques to fix or modify mutations that cause disease in patients with rare genetic disorders. It works to restore normal gene function, halt disease progression, and create personalized treatment options for conditions that presently have few or no therapies. This method focuses on tackling the underlying cause of the disease at the DNA level instead of merely addressing the symptoms.

The primary technologies employed in rare disease genome editing include clustered regularly interspaced short palindromic repeats (CRISPR) or CRISPR-associated protein 9, transcription activator-like effector nucleases (TALEN), zinc finger nucleases (ZFN), and others. Clustered regularly interspaced short palindromic repeats (CRISPR) or CRISPR-associated protein 9 is a genome editing tool that utilizes a guide RNA and the Cas9 enzyme to accurately cut and modify DNA for research and therapeutic applications. It is applied to various disease types such as monogenic disorders, multifactorial disorders, and chromosomal disorders, and is used in both therapeutics and research, serving end users including biotechnology and pharmaceutical companies, academic and government research institutes, and hospitals.

Tariffs are influencing the rare disease genome editing market by increasing costs of imported enzymes, nucleases, vectors, sequencing tools, and advanced laboratory equipment essential for genome editing workflows. Biotechnology firms and research institutes in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces cost escalation in reagent manufacturing and exports. These tariffs are increasing development costs and slowing translational research timelines. However, they are also encouraging domestic reagent production, regional biomanufacturing expansion, and localized innovation in genome editing platforms.

The rare disease genome editing market research report is one of a series of new reports from The Business Research Company that provides rare disease genome editing market statistics, including rare disease genome editing industry global market size, regional shares, competitors with a rare disease genome editing market share, detailed rare disease genome editing market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease genome editing industry. This rare disease genome editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare disease genome editing market size has grown rapidly in recent years. It will grow from $1.29 billion in 2025 to $1.51 billion in 2026 at a compound annual growth rate (CAGR) of 17.8%. The growth in the historic period can be attributed to advancements in gene editing technologies, increasing identification of rare genetic mutations, expansion of genomic research funding, early success of gene therapy trials, growing academic research initiatives.

The rare disease genome editing market size is expected to see rapid growth in the next few years. It will grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing investment in curative rare disease therapies, rising adoption of precision medicine approaches, expansion of clinical genome editing trials, growing regulatory support for orphan drugs, increasing collaboration between biotech and healthcare providers. Major trends in the forecast period include increasing adoption of crispr-based therapeutics, rising focus on gene editing for monogenic disorders, growing use of personalized genome editing approaches, expansion of advanced editing platforms, enhanced integration of genomic data analytics.

The growing emphasis on precision medicine is expected to drive the expansion of the rare disease genome editing market in the coming years. Precision medicine refers to a customized healthcare approach that utilizes a patient's genetics, environment, and lifestyle to deliver more accurate and effective treatments. This increased focus on precision medicine is fueled by advancements in genomic sequencing and biomarker identification, which allow for precise detection and targeted therapies. The rare disease genome editing market supports precision medicine by facilitating targeted correction of genetic mutations, making treatments more personalized and effective. It advances healthcare by addressing the underlying causes of rare disorders, improving patient outcomes, and reducing dependence on symptomatic management. For example, in March 2024, Novotech, an Australia-based biotechnology company, reported that in 2023, 43% of the 217 FDA-approved oncology therapies were precision oncology treatments, with 78 incorporating DNA or NGS-detectable biomarkers. As a result, the growing emphasis on precision medicine is propelling the growth of the rare disease genome editing market.

Major companies operating in the rare disease genome editing market are concentrating on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, to improve treatment precision, enhance therapeutic outcomes, and target previously untreatable genetic disorders. CRISPR-based gene editing systems are innovative technologies that allow precise modifications to the genome, enabling the correction of genetic defects or the introduction of therapeutic genes into cells. For example, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, collaborated with CRISPR Therapeutics Inc., a US-based biotechnology research company, and obtained conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). It is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy functions by editing a patient's hematopoietic stem cells to reactivate fetal hemoglobin production, which alleviates or eliminates disease symptoms and provides a potential functional cure for these conditions.

In May 2024, Arbor Biotechnologies Inc., a US-based biotechnology firm, acquired Serendipity Biosciences for an undisclosed amount. Through this acquisition, Arbor sought to enhance its technological capabilities by incorporating Serendipity's innovative gene-editing platforms, including Fanzor-based and IsrB-based systems, to broaden its therapeutic applications, particularly in reverse transcriptase-based editing and large DNA insertions. Serendipity Biosciences Inc. is a US-based biotechnology company focused on the discovery and development of distinctive, programmable gene-editing technologies.

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rare disease genome editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare disease genome editing market consists of revenues earned by entities by providing services such as gene editing therapy development, genetic testing and diagnostics, preclinical research and validation, clinical trial management, and regulatory consulting for genome-based therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare disease genome editing market also includes sales of zinc finger nucleases, delivery vectors, modified cells, and therapeutic genome-editing formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Disease Genome Editing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses rare disease genome editing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare disease genome editing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare disease genome editing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9; Transcription Activator-Like Effector Nucleases (TALEN); Zinc Finger Nucleases (ZFN); Other Technologies
• 2) By Disease Type: Monogenic Disorders; Multifactorial Disorders; Chromosomal Disorders
• 3) By Application: Therapeutics; Research
• 4) By End User: Biotechnology And Pharmaceutical Companies; Academic And Government Research Institutes; Hospitals
• Subsegments:
• 1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13; Base Editing; Prime Editing
• 2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN); Designer Transcription Activator-Like Effector Nucleases (dTALEN); Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
• 3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN); Engineered Zinc Finger Nucleases (ZFN); Modular Zinc Finger Nucleases (ZFN)
• 4) By Other Technologies: Meganucleases; Ribonucleic Acid (RNA)-Guided Nucleases; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases
• Companies Mentioned: Regeneron Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Ultragenyx Pharmaceutical Inc.; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Rocket Pharmaceuticals Inc.; Sangamo Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Editas Medicine Inc.; Krystal Biotech Inc.; Caribou Biosciences Inc; Bluebird Bio Inc.; SpliceBio S.L.; Cellectis SA; Generation Bio Co.; iECURE Inc.; Affinia Therapeutics Inc.; Precision Biosciences Inc.; Intellia Therapeutics Inc.; MeiraGTx Holdings plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.